The PDE4 Inhibitors Roflumilast and Rolipram Rescue ADO2 Osteoclast Resorption Dysfunction

• Published in: Calcified tissue international Vol. 114; no. 4; pp. 430 - 443
• Main Authors: Hong, Jung Min, Gerard-O’Riley, Rita L., Acton, Dena, Alam, Imranul, Econs, Michael J., Bruzzaniti, Angela
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.04.2024; Springer Nature B.V
• Subjects: Acidification; Acids; Adenylate cyclase; Adenylyl Cyclases - metabolism; Aminopyridines; Animals; Antagonists; Benzamides; Biochemistry; Biomedical and Life Sciences; Bone diseases; Bone mass; Bone resorption; Bone Resorption - drug therapy; Bone Resorption - metabolism; Cell Biology; Chloride; Chloride Channels - genetics; Chronic obstructive pulmonary disease; Cyclic AMP; Cyclopropanes; Drug dosages; Endocrinology; Forskolin; Humans; Investigations; Kinases; Life Sciences; Mice; Missense mutation; Mutation; Original Research; Orthopedics; Osteoclasts; Osteoclasts - metabolism; Osteopetrosis; Phosphatase; Phosphodiesterase; Phosphodiesterase 4 Inhibitors - metabolism; Phosphodiesterase 4 Inhibitors - pharmacology; Phosphodiesterase IV; Rolipram; Rolipram - metabolism; Rolipram - pharmacology; Software; Osteoclast; Osteopetrosis; cAMP; Chloride channel 7; Forskolin; Phosphodiesterase
• ISSN: 1432-0827; 0171-967X; 1432-0827
• DOI: 10.1007/s00223-024-01191-7

Autosomal Dominant Osteopetrosis type II (ADO2) is a rare bone disease of impaired osteoclastic bone resorption caused by heterozygous missense mutations in the chloride channel 7 (CLCN7). Adenylate cyclase, which catalyzes the formation of cAMP, is critical for lysosomal acidification in osteoclasts. We found reduced cAMP levels in ADO2 osteoclasts compared to wild-type (WT) osteoclasts, leading us to examine whether regulating cAMP would improve ADO2 osteoclast activity. Although forskolin, a known activator of adenylate cyclase and cAMP levels, negatively affected osteoclast number, it led to an overall increase in ADO2 and WT osteoclast resorption activity in vitro. Next, we examined cAMP hydrolysis by the phosphodiesterase 4 (PDE4) proteins in ADO2 versus WT osteoclasts. QPCR analysis revealed higher expression of the three major PDE4 subtypes (4a, 4b, 4d) in ADO2 osteoclasts compared in WT, consistent with reduced cAMP levels in ADO2 osteoclasts. In addition, we found that the PDE4 antagonists, rolipram and roflumilast, stimulated ADO2 and WT osteoclast formation in a dose-dependent manner. Importantly, roflumilast and rolipram displayed a concentration-dependent increase in osteoclast resorption activity which was greater in ADO2 than WT osteoclasts. Moreover, treatment with roflumilast rescued cAMP levels in ADO2 OCLs. The key findings from our studies demonstrate that osteoclasts from ADO2 mice exhibit reduced cAMP levels and PDE4 inhibition rescues cAMP levels and ADO2 osteoclast activity dysfunction in vitro. The mechanism of action of PDE4 inhibitors and their ability to reduce the high bone mass of ADO2 mice in vivo are currently under investigation. Importantly, these studies advance the understanding of the mechanisms underlying the ADO2 osteoclast dysfunction which is critical for the development of therapeutic approaches to treat clinically affected ADO2 patients.